JP2024520790A - Ｋｌｋ２－ｇｐｉ融合タンパク質をコードする核酸、組換え細胞、及びその使用 - Google Patents

Ｋｌｋ２－ｇｐｉ融合タンパク質をコードする核酸、組換え細胞、及びその使用 Download PDF

Info

Publication number
JP2024520790A
JP2024520790A JP2023575724A JP2023575724A JP2024520790A JP 2024520790 A JP2024520790 A JP 2024520790A JP 2023575724 A JP2023575724 A JP 2023575724A JP 2023575724 A JP2023575724 A JP 2023575724A JP 2024520790 A JP2024520790 A JP 2024520790A
Authority
JP
Japan
Prior art keywords
kallikrein
cells
sequence
preparation
gpi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575724A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520790A5 (enExample
Inventor
エル． エマニュエル，スチュアート
ジェイ． ルトコスキ，トーマス
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2024520790A publication Critical patent/JP2024520790A/ja
Publication of JP2024520790A5 publication Critical patent/JP2024520790A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21035—Tissue kallikrein (3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • C07K2319/912—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation containing a GPI (phosphatidyl-inositol glycane) anchor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2023575724A 2021-06-10 2022-06-08 Ｋｌｋ２－ｇｐｉ融合タンパク質をコードする核酸、組換え細胞、及びその使用 Pending JP2024520790A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163209019P 2021-06-10 2021-06-10
US63/209,019 2021-06-10
PCT/IB2022/055355 WO2022259190A1 (en) 2021-06-10 2022-06-08 Nucleic acid coding for klk2-gpi fusion protein, recombinant cells, and uses thereof

Publications (2)

Publication Number Publication Date
JP2024520790A true JP2024520790A (ja) 2024-05-24
JP2024520790A5 JP2024520790A5 (enExample) 2025-06-11

Family

ID=82358484

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575724A Pending JP2024520790A (ja) 2021-06-10 2022-06-08 Ｋｌｋ２－ｇｐｉ融合タンパク質をコードする核酸、組換え細胞、及びその使用

Country Status (11)

Country Link
US (1) US20220403397A1 (enExample)
EP (1) EP4352217A1 (enExample)
JP (1) JP2024520790A (enExample)
KR (1) KR20240021211A (enExample)
CN (1) CN117480253A (enExample)
AU (1) AU2022291273A1 (enExample)
BR (1) BR112023025616A2 (enExample)
CA (1) CA3222756A1 (enExample)
IL (1) IL309179A (enExample)
MX (1) MX2023014793A (enExample)
WO (1) WO2022259190A1 (enExample)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5602299A (en) 1992-09-23 1997-02-11 Mount Sinai School Of Medicine Of The City University Of New York Transgenic animal models for neurodegenerative disease
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
US5516639A (en) * 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
JPH07132033A (ja) 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US6113917A (en) * 1995-04-25 2000-09-05 Rmf Dictagene S.A. Modified polypeptides for enhanced immunogenicity
US6066778A (en) 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
DK1716233T3 (da) * 2004-01-30 2009-10-26 Maxygen Holdings Ltd Reguleret stopkodongennemlæsning
AU2005295421A1 (en) * 2004-10-18 2006-04-27 Zymogenetics, Inc. Soluble Zcytor21, anti-Zcytor21 antibodies and binding partners and methods of using in inflammation
EP2315846A4 (en) * 2008-08-05 2011-11-30 Univ Rochester PSA AND KLK2 AS THERAPEUTIC TARGET MOLECULES AND PSA AND KLK2-INHIBITABLE MOLECULES
WO2012068317A2 (en) * 2010-11-16 2012-05-24 Excelimmune, Inc. Methods for producing recombinant proteins
JP7235436B2 (ja) * 2014-11-10 2023-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 細胞の表面上にポリペプチドを発現させるための組成物および方法
AU2020322221A1 (en) * 2019-07-26 2022-03-24 Janssen Biotech, Inc. Anti-hK2 chimeric antigen receptor (CAR)

Also Published As

Publication number Publication date
EP4352217A1 (en) 2024-04-17
CN117480253A (zh) 2024-01-30
MX2023014793A (es) 2024-03-25
US20220403397A1 (en) 2022-12-22
AU2022291273A1 (en) 2024-01-25
KR20240021211A (ko) 2024-02-16
BR112023025616A2 (pt) 2024-02-27
WO2022259190A1 (en) 2022-12-15
CA3222756A1 (en) 2022-12-15
IL309179A (en) 2024-02-01

Similar Documents

Publication Publication Date Title
Friis et al. A matriptase-prostasin reciprocal zymogen activation complex with unique features: prostasin as a non-enzymatic co-factor for matriptase activation
BR112019028024A2 (pt) método para controlar o nível de uma sequência de polipeptídeos, receptor de antígeno quimérico, proteína de fusão, polinucleotídeo isolado, vetor de expressão, célula, composição farmacêutica, e, método para engenheirar uma célula imunomodulatória.
US8993742B2 (en) Tubulo-vesicular structure localization signals
JP2007536931A (ja) 新規の遺伝子破壊、組成物およびそれらに関連する方法
US6100444A (en) Prostate specific regulatory nucleic acid sequences and transgenic non-human animals expressing prostate specific antigen
JP2019504631A (ja) 組換えｃｘａｄｒ発現のための組成物および方法
US20220403397A1 (en) Nucleic acid constructs encoding kallikrein-2 fusion protein and vectors, preparations of cells, and methods of use thereof
US7265260B2 (en) Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors
US20120096568A1 (en) Transgenic lsd1 animal model for cancer
EA007273B1 (ru) Выделенный полипептид, связывающийся с каспазой -8, и способы его применения
EP1148779B1 (en) Expression of secreted human alpha-fetoprotein in transgenic animals
US20110283375A1 (en) Transgenic Prothrombin And Related Thrombin Precursors And Transgenics, Methods, Compositions, Uses And The Like Relating Thereto
AU2020234518A1 (en) Optimised RAG1 deficient gene therapy
JP2002360120A (ja) 優性ネガティブ変異形のＰ１−３キナーゼｐ８５サブユニットを含むトランスジェニック動物
CZ160198A3 (cs) Transgenní zvíře, transgen, způsob jejich přípravy a použití pro purifikaci transkripčních komplexů
EP2271206A1 (fr) Lapins transgeniques producteurs de facteur vii humain
Stephan et al. Analysis of the Functional Interaction of Neurotrypsin and Agrin in the Murine Central Nervous System
JPH0779773A (ja) 癌細胞株
JP2025527411A (ja) キメラｃ－ｋｉｔタンパク質を発現するトランスジェニック動物
JP2005027672A (ja) ｐ２５ポリペプチドをコードするトランスジーンを有するトランスジェニック非ヒト動物及びトランスジェニック非ヒト哺乳類細胞
Cobaleda et al. A non-human animal model of mucosa-associated lymphoid tissue (MALT) lymphoma
Reid Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon: C. Oefner, A. D'Arcy, M. Hennig, et al. J Mol Biol 296: 341–349, 2000
Song FGF8, isoform b, is an etiological factor in prostate tumorigenesis
Reid Expression of Kell blood group protein in nonerythroid tissues: D. Russo, X. Wu, CM Redman, et al. Blood 96: 340–346, 2000
Wylie et al. Animal Model

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250603

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260428